Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
BMC Microbiol ; 20(1): 8, 2020 01 09.
Article in English | MEDLINE | ID: mdl-31918661

ABSTRACT

BACKGROUND: Francisella noatunensis subsp. orientalis (Fno) is the etiological agent of francisellosis in cultured warm water fish, such as tilapia. Antibiotics are administered to treat the disease but a better understanding of Fno infection biology will inform improved treatment and prevention measures. However, studies with native hosts are costly and considerable benefits would derive from access to a practical alternative host. Here, larvae of Galleria mellonella were assessed for suitability to study Fno virulence. RESULTS: Larvae were killed by Fno in a dose-dependent manner but the insects could be rescued from lethal doses of bacteria by antibiotic therapy. Infection progression was assessed by histopathology (haematoxylin and eosin staining, Gram Twort and immunohistochemistry) and enumeration of bacteria recovered from the larval haemolymph on selective agar. Fno was phagocytosed and could survive intracellularly, which is consistent with observations in fish. Virulence of five Fno isolates showed strong agreement between G. mellonella and red Nile tilapia hosts. CONCLUSIONS: This study shows that an alternative host, G. mellonella, can be applied to understand Fno infections, which will assist efforts to identify solutions to piscine francisellosis thus securing the livelihoods of tilapia farmers worldwide and ensuring the production of this important food source.


Subject(s)
Anti-Bacterial Agents/pharmacology , Francisella/pathogenicity , Moths/microbiology , Animals , Fish Diseases/microbiology , Francisella/drug effects , Larva/drug effects , Larva/microbiology , Microbial Viability , Moths/drug effects , Phagocytosis , Tilapia/microbiology
2.
Inorg Chem ; 59(9): 6242-6254, 2020 May 04.
Article in English | MEDLINE | ID: mdl-32286066

ABSTRACT

The urgency of finding novel antibacterial drugs (not only antibiotics), exhibiting different mechanisms of therapeutic action, is significant and has served as a premise for recognizing bacteria's siderophores as a plausible drug target. Bacteria secrete siderophores in order to sequester iron(III) from the surrounding medium by binding the essential metal with high affinity. Gallium, on the other hand, is an "abiogenic" ion, known for its anticancer, antibacterial, and anti-inflammatory action. The rationale behind its therapeutic effect lies in its close mimicry of the ferric ion. Since both ions share various physicochemical characteristics, it is of particular interest to understand if gallium could compete with the native ferric ion for binding siderophores and to decipher which molecular characteristics favor Ga3+ binding over Fe3+ binding. It is also well-known that some bacteria are susceptible to gallium-based therapy, while others are not. Therefore, many questions arise such as the following: (1) Which main group/groups building the siderophores promote gallium's attack? (2) Does the combination of the building blocks affect the preference toward a metal? (3) Does the environment play a crucial role? (4) Could the pH of the medium influence the balance between the ions? We try to address these questions by evaluating the free energy of the competition between Ga3+ and Fe3+ ions for siderophore ligands of various structures, denticities, and charge states by employing the tools of the computational chemistry at the DFT/SMD level. Our results not only fall in line with recent experimental data but also complement our knowledge about "Trojan horse" gallium-based therapy.


Subject(s)
Anti-Bacterial Agents/pharmacology , Density Functional Theory , Ferric Compounds/pharmacology , Gallium/pharmacology , Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/chemistry , Binding Sites/drug effects , Ferric Compounds/chemistry , Francisella/drug effects , Gallium/chemistry , Hydrogen-Ion Concentration , Klebsiella pneumoniae/drug effects , Microbial Sensitivity Tests , Models, Molecular , Molecular Structure , Mycobacterium tuberculosis/drug effects , Pseudomonas aeruginosa/drug effects , Static Electricity
3.
Int J Mol Sci ; 21(5)2020 Feb 29.
Article in English | MEDLINE | ID: mdl-32121349

ABSTRACT

A dramatic increase in global antimicrobial resistance (AMR) has been well documented. Of particular concern is the dearth of information regarding the spectrum and prevalence of AMR within Category A Select Agents. Here, we performed a survey of horizontally and vertically transferred AMR determinants among Category A agents and their near neighbors. Microarrays provided broad spectrum screening of 127 Francisella spp., Yersinia spp., and Bacillus spp. strains for the presence/absence of 500+ AMR genes (or families of genes). Detecting a broad variety of AMR genes in each genus, microarray analysis also picked up the presence of an engineered plasmid in a Y. pestis strain. High resolution melt analysis (HRMA) was also used to assess the presence of quinolone resistance-associated mutations in 100 of these strains. Though HRMA was able to detect resistance-causing point mutations in B. anthracis strains, it was not capable of discriminating these point mutations from other nucleotide substitutions (e.g., arising from sequence differences in near neighbors). Though these technologies are well-established, to our knowledge, this is the largest survey of Category A agents and their near-neighbor species for genes covering multiple mechanisms of AMR.


Subject(s)
Bacterial Infections/genetics , Drug Resistance, Bacterial/genetics , Quinolones/therapeutic use , Bacillus/drug effects , Bacillus/genetics , Bacillus/pathogenicity , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Francisella/drug effects , Francisella/genetics , Francisella/pathogenicity , Gene Expression Regulation, Bacterial/drug effects , Humans , Mutation/genetics , Plasmids/genetics , Yersinia/drug effects , Yersinia/genetics , Yersinia/pathogenicity
4.
Article in English | MEDLINE | ID: mdl-28167561

ABSTRACT

Fluoroquinolone (FQ) resistance is a major health concern in the treatment of tularemia. Because DNA gyrase has been described as the main target of these compounds, our aim was to clarify the contributions of both GyrA and GyrB mutations found in Francisella novicida clones highly resistant to FQs. Wild-type and mutated GyrA and GyrB subunits were overexpressed so that the in vitro FQ sensitivity of functional reconstituted complexes could be evaluated. The data obtained were compared to the MICs of FQs against bacterial clones harboring the same mutations and were further validated through complementation experiments and structural modeling. Whole-genome sequencing of highly FQ-resistant lineages was also done. Supercoiling and DNA cleavage assays demonstrated that GyrA D87 is a hot spot FQ resistance target in F. novicida and pointed out the role of the GyrA P43H substitution in resistance acquisition. An unusual feature of FQ resistance acquisition in F. novicida is that the first-step mutation occurs in GyrB, with direct or indirect consequences for FQ sensitivity. Insertion of P466 into GyrB leads to a 50% inhibitory concentration (IC50) comparable to that observed for a mutant gyrase carrying the GyrA D87Y substitution, while the D487E-ΔK488 mutation, while not active on its own, contributes to the high level of resistance that occurs following acquisition of the GyrA D87G substitution in double GyrA/GyrB mutants. The involvement of other putative targets is discussed, including that of a ParE mutation that was found to arise in the very late stage of antibiotic exposure. This study provides the first characterization of the molecular mechanisms responsible for FQ resistance in Francisella.


Subject(s)
DNA Gyrase/genetics , DNA Topoisomerase IV/genetics , Drug Resistance, Bacterial/genetics , Francisella/genetics , Genome, Bacterial , Mutation , Amino Acid Motifs , Amino Acid Substitution , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Binding Sites , Cloning, Molecular , DNA Gyrase/chemistry , DNA Gyrase/metabolism , DNA Topoisomerase IV/chemistry , DNA Topoisomerase IV/metabolism , Escherichia coli/genetics , Escherichia coli/metabolism , Fluoroquinolones/chemistry , Fluoroquinolones/pharmacology , Francisella/drug effects , Francisella/enzymology , Francisella/growth & development , Gene Expression , High-Throughput Nucleotide Sequencing , Microbial Sensitivity Tests , Models, Molecular , Protein Binding , Protein Conformation, alpha-Helical , Protein Conformation, beta-Strand , Protein Interaction Domains and Motifs , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
5.
Microb Pathog ; 109: 313-318, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28478203

ABSTRACT

Francisella novicida is a gram-negative pathogen commonly used to study infections by the potential bioterrorism agent, Francisella tularensis. The Francisella lipid A structure has been well characterized and showed to affect the pathogenesis of F. novicida. Previous work characterized two lipid A acyltransferases, LpxD1 and LpxD2, and constructed the lpxD1-null and lpxD2-null mutants. Mutational analysis showed the lpxD1-null mutant was attenuated in mice and subsequently exhibited protection against a lethal WT challenge. However, details as how the virulence has been changed have remained elusive. This study aims to analyze effects of lipid A acyltransferases on the pathogenesis of F. novicida. MS and MSn were conducted to confirm the lipid A structures of lpxD1-null and lpxD2-null mutants. The stress tolerance, Toll-like receptor 4 (TLR4) stimulation level, intracellular survival and replication ability and cytotoxicity of lpxD1-null and lpxD2-null mutants were analyzed. The results suggested the lpxD1-null mutant with shorter acyl chains in lipid A is more sensitive to various environmental stresses than F. novicida and lpxD2-null mutant. In addition, the lpxD1-null mutant fails to survive and replicate in cells and shows lower cytotoxicity to infected cells. This study provides insights into the pathogenesis of F. novicida.


Subject(s)
Acyltransferases/pharmacology , Francisella/drug effects , Francisella/pathogenicity , Lipid A/chemistry , Virulence , Animals , Bacterial Proteins/genetics , Cell Line , Francisella/chemistry , Francisella/genetics , Genes, Bacterial/genetics , Humans , Lipid A/isolation & purification , Lipid A/metabolism , Mice , Mutation , RAW 264.7 Cells , THP-1 Cells , Toll-Like Receptor 4
6.
Fish Shellfish Immunol ; 67: 571-574, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28634011

ABSTRACT

The development of vaccines for aquaculture has been an important milestone in providing a continuous and sustainable production. Most of the vaccines currently on the market for aquaculture include oil as adjuvant. Nevertheless, several studies reported an occurrence of side effects after their use in farmed fish. As a result, there is a need for new and improved adjuvants that can stimulate the immune system while causing as few side-effects as possible. Hemocyanins are versatile macromolecules with strong immunogenic and immunomodulatory properties. Due to these characteristics, hemocyanin from Concholepas concholepas (CCH) has been biochemically characterized and evaluated as vaccine adjuvant in mice and humans. Francisellosis is a chronic granulomatous disease, which can result in high mortality depending on the host. The disease is caused by the facultative intracellular Gram-negative bacteria Francisella noatunensis, which remains an unsolved problem for the aquaculture, as no efficient vaccines are available. The aim of the present work was to investigate the immunoregulatory properties of CCH against francisellosis in an experimental zebrafish model. When immunized with CCH, zebrafish were protected from subsequent challenge with a lethal dose of Francisella noatunensis subsp. orientalis. Subsequently the mRNA expression levels of several immune-related genes were studied, including mhcii, il12a, tnfα and ifng1-1. Taken together, the data report the immunoregulatory properties of CCH and its potential use as a vaccine adjuvant for aquaculture.


Subject(s)
Adjuvants, Immunologic/pharmacology , Fish Diseases/immunology , Francisella/drug effects , Gastropoda/chemistry , Gram-Negative Bacterial Infections/veterinary , Hemocyanins/pharmacology , Zebrafish , Animals , Gram-Negative Bacterial Infections/immunology
7.
Biochem J ; 470(2): 243-53, 2015 Sep 01.
Article in English | MEDLINE | ID: mdl-26188040

ABSTRACT

In addition to membrane disruption, the cathelicidin antimicrobial peptide (AMP) LL-37 translocates through the bacterial inner membrane to target intracellular molecules. The present study aims to identify an alternate mechanism and a cytoplasmic target of LL-37 in Francisella. LL-37 binding proteins from Francisella novicida U112 bacterial lysates were precipitated by using biotinylated LL-37 (B-LL-37) and NeutrAvidin-agarose beads. Bound proteins were identified by LC-MS/MS, validated and characterized by bead pull-down assays and differential scanning fluorimetry (DSF). The cationic AMP (CAMP) LL-37 was able to interact with Francisella cytoplasmic acyl carrier protein (AcpP; FTN1340/FTT1376). Further study confirmed that LL-37 peptide could bind to AcpP and that the sheep cathelicidin SMAP-29 (Sheep Myeloid Antimicrobial Peptide 29) further increased LL-37 binding to AcpP, suggesting a synergistic effect of SMAP-29 on the binding. LL-37 could also bind to both AcpP of Escherichia coli and Bacillus anthracis, implying a mechanism of broad action of LL-37-AcpP binding. Overexpression of the acpP gene in F. novicida led to an increase in LL-37 susceptibility. LL-37 binding to AcpP changed the fatty acid composition profiles. Taken together, we identified a novel cytoplasmic target of LL-37 in Francisella, suggesting a mechanism of action of this peptide beyond membrane permeabilization. Our findings highlight a novel mechanism of antimicrobial activity of this peptide and document a previously unexplored target of α-helical CAMPs.


Subject(s)
Acyl Carrier Protein/metabolism , Anti-Bacterial Agents/metabolism , Antimicrobial Cationic Peptides/metabolism , Bacterial Proteins/metabolism , Francisella/metabolism , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Antimicrobial Cationic Peptides/pharmacology , Cytoplasm/metabolism , Fatty Acids/metabolism , Francisella/drug effects , Models, Molecular , Molecular Sequence Data , Protein Binding , Cathelicidins
8.
Dis Aquat Organ ; 121(2): 149-159, 2016 09 26.
Article in English | MEDLINE | ID: mdl-27667812

ABSTRACT

Systemic infection caused by the facultative intracellular bacterium Francisella noatunensis subsp. noatunensis remains a disease threat to Atlantic cod Gadus morhua L. Future prophylactics could benefit from better knowledge on how the bacterium invades, survives and establishes infection in its host cells. Here, facilitated by the use of a gentamicin protection assay, this was studied in primary monocyte/macrophage cultures and an epithelial-like cell line derived from Atlantic cod larvae (ACL cells). The results showed that F. noatunensis subsp. noatunensis is able to invade primary monocyte/macrophages, and that the actin-polymerisation inhibitor cytochalasin D blocked internalisation, demonstrating that the invasion is mediated through phagocytosis. Interferon gamma (IFNγ) treatment of cod macrophages prior to infection enhanced bacterial invasion, potentially by stimulating macrophage activation in an early step in host defence against F. noatunensis subsp. noatunensis infections. We measured a rapid drop of the initial high levels of internalised bacteria in macrophages, indicating the presence and action of a cellular immune defence mechanism before intracellular bacterial replication took place. Low levels of bacterial internalisation and replication were detected in the epithelial-like ACL cells. The capacity of F. noatunensis subsp. noatunensis to enter, survive and even replicate within an epithelial cell line may play an important role in its ability to infect live fish and transverse epithelial barriers to reach the bacterium's main target cells-the macrophage.


Subject(s)
Bacteriological Techniques , Francisella/isolation & purification , Macrophages/microbiology , Animals , Anti-Bacterial Agents/pharmacology , Cells, Cultured , Drug Resistance, Bacterial , Francisella/drug effects , Gadus morhua , Gentamicins/pharmacology
9.
J Aquat Anim Health ; 28(3): 199-207, 2016 09.
Article in English | MEDLINE | ID: mdl-27484609

ABSTRACT

In this project we optimized a minimal inhibitory concentration testing protocol for Francisella noatunensis orientalis. Thirty-three F. noatunensis orientalis isolates recovered from different fish species and locations were tested, and Escherichia coli ATCC 25922 was used as a quality control reference strain. A modified cation-adjusted Mueller Hinton broth supplemented with 2% IsoVitalex and 0.1% glucose (MMH) was tested at a pH of 6.4 ± 0.1, 7.1 ± 0.1, and 7.3 ± 0.1. Growth curves generated for F. noatunensis orientalis indicated that MMH at a pH of 6.4 ± 0.1 provided optimal growth. There were no significant differences in the growth curves obtained from isolates recovered from different fish species or from fresh or marine water. The pH of 6.4 ± 0.1 in the MMH media interfered with the inhibitory properties of the potentiated sulfonamides (ormetoprim-sulfadimethoxine and trimethoprim-sulfamethoxazole) when using the E. coli ATCC reference strain. Minimal inhibitory concentrations of eight antimicrobials (gentamicin, enrofloxacin, ampicillin, oxytetracycline, erythromycin, florfenicol, flumequine, and oxolinic acid) were similar for all F. noatunensis orientalis isolates. The in vitro susceptibility data provided here can provide a baseline for monitoring the development of antimicrobial resistance among F. noatunensis orientalis isolates, as well as provide valuable data in the development of potential therapeutics. Received October 27, 2015; accepted April 13, 2016.


Subject(s)
Anti-Bacterial Agents/pharmacology , Francisella/drug effects , Microbial Sensitivity Tests/methods , Animals , Drug Resistance, Bacterial
10.
J Antimicrob Chemother ; 69(1): 101-10, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23963236

ABSTRACT

OBJECTIVES: Francisella tularensis, a CDC class A potential bioterrorism agent, is a Gram-negative bacterium responsible for tularaemia. Understanding the mechanisms of resistance to antibiotics used as first-line treatment is of major security relevance. METHODS: We propagated the three parental reference strains Francisella tularensis subsp. holarctica live vaccine strain, Francisella novicida and Francisella philomiragia with increasing concentrations of ciprofloxacin, a fluoroquinolone used as curative and prophylactic treatment for tularaemia. This evolution procedure provided us with high-level ciprofloxacin-resistant mutants and all evolutionary intermediates towards high-level resistance. We determined the resistance levels to other fluoroquinolones (levofloxacin and moxifloxacin) and other antibiotic families (aminoglycosides, tetracyclines and macrolides) and characterized the genetic changes in the fluoroquinolone target genes encoding DNA gyrase and topoisomerase IV. RESULTS: All high-level resistant mutants shared cross-resistance to the tested fluoroquinolones, while some also revealed striking levels of cross-resistance to other clinically relevant antibiotic classes. High-level resistant mutants carried one to three mutations, including some not previously reported. We mapped all mutations onto known topoisomerase three-dimensional structures. Along the pathways towards high-level resistance, we identified complex evolutionary trajectories including polymorphic states and additional resistance mechanisms likely to be associated with efflux processes. CONCLUSIONS: Our data demonstrated the efficiency and speed of in vitro production of mutants highly resistant to fluoroquinolones in Francisella species. They emphasize the urgent need to identify all antibiotic resistance mechanisms in these species, develop molecular tools for their detection and design new therapeutic alternatives for tularaemia.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Fluoroquinolones/pharmacology , Francisella/drug effects , DNA Gyrase/genetics , DNA Mutational Analysis , DNA Topoisomerase IV/genetics , Francisella/enzymology , Francisella/genetics , Francisella/growth & development , Humans , Microbial Sensitivity Tests , Selection, Genetic , Serial Passage
11.
J Appl Microbiol ; 117(2): 397-404, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24807242

ABSTRACT

AIM: The aim of the study was to develop test methods and evaluate survival of Francisella philomiragia cells and MS2 bacteriophage after exposure to PES-Solid (a solid source of peracetic acid) formulations with or without surfactants. METHODS AND RESULTS: Francisella philomiragia cells (≥7·6 log10 CFU) or MS2 bacteriophage (≥6·8 log10 PFU) were deposited on seven different test materials and treated with three different PES-Solid formulations, three different preneutralized samples and filter controls at room temperature for 15 min. There were 0-1·3 log10 CFU (<20 cells) of cell survival, or 0-1·7 log10 (<51 PFU) of bacteriophage survival in all 21 test combinations (organism, formulation and substrate) containing reactive PES-Solid. In addition, the microemulsion (Dahlgren Surfactant System) showed ≤2 log10 (100 cells) of viable F. philomiragia cells, indicating the microemulsion achieved <2 log10 CFU on its own. CONCLUSIONS: Three PES-Solid formulations and one microemulsion system (DSS) inactivated F. philomiragia cells and/or MS2 bacteriophage that were deposited on seven different materials. SIGNIFICANCE AND IMPACT OF THE STUDY: A test method was developed to show that reactive PES-Solid formulations and a microemulsion system (DSS) inactivated >6 log10 CFU/PFU F. philomiragia cells and/or MS2 bacteriophage on different materials.


Subject(s)
Decontamination/methods , Disinfectants/pharmacology , Disinfection/methods , Francisella/drug effects , Levivirus/drug effects , Peracetic Acid/pharmacology , Microbial Viability/drug effects , Surface-Active Agents
12.
J Zoo Wildl Med ; 45(3): 727-31, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25314854

ABSTRACT

Francisella noatunensis is an emerging pathogen of fish that has been isolated from several cultured species worldwide. Here presented is a case involving several hundred marine grunts that were caught near the Florida Keys for display in public aquaria. These fish were maintained in a recirculating system where they began to experience mortalities approximately two weeks post-stocking. Postmortem examination revealed disseminated systemic granulomatous disease most severely affecting spleen and kidney. Splenic and renal tissue homogenates inoculated in modified Thayer Martin agar media yielded colonies consistent with F. noatunensis 4 days post inoculation. Bacterial colonies and tissues were confirmed positive after real-time PCR amplification of the intracellular growth loci gene (iglC) specific for F. noatunensis subspecies orientalis. Consequently, multiple novel host species for this pathogen were identified, including the French grunt (Haemulon flavolineatum) and the Caesar grunt (Haemulon carbonarium).


Subject(s)
Fish Diseases/microbiology , Francisella/classification , Francisella/isolation & purification , Animals , Anti-Bacterial Agents/pharmacology , Communicable Diseases, Emerging/veterinary , Drug Resistance, Bacterial , Fishes , Francisella/drug effects
14.
Infect Immun ; 80(12): 4239-47, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22988021

ABSTRACT

Francisella tularensis is a gram-negative bacterium that is highly virulent in humans, causing the disease tularemia. F. novicida is closely related to F. tularensis and exhibits high virulence in mice, but it is avirulent in healthy humans. An F. novicida-specific gene cluster (FTN0451 to FTN0456) encodes two proteins with diguanylate cyclase (DGC) and phosphodiesterase (PDE) domains that modulate the synthesis and degradation of cyclic di-GMP (cdGMP). No DGC- or PDE-encoding protein genes are present in the F. tularensis genome. F. novicida strains lacking either the two DGC/PDE genes (cdgA and cdgB) or the entire gene cluster (strain KKF457) are defective for biofilm formation. In addition, expression of CdgB or a heterologous DGC in strain KKF457 stimulated F. novicida biofilms, even in a strain lacking the biofilm regulator QseB. Genetic evidence suggests that CdgA is predominantly a PDE, while CdgB is predominantly a DGC. The F. novicida qseB strain showed reduced cdgA and cdgB transcript levels, demonstrating an F. novicida biofilm signaling cascade that controls cdGMP levels. Interestingly, KKF457 with elevated cdGMP levels exhibited a decrease in intramacrophage replication and virulence in mice, as well as increased growth yields and biofilm formation in vitro. Microarray analyses revealed that cdGMP stimulated the transcription of a chitinase (ChiB) known to contribute to biofilm formation. Our results indicate that elevated cdGMP in F. novicida stimulates biofilm formation and inhibits virulence. We suggest that differences in human virulence between F. novicida and F. tularensis may be due in part to the absence of cdGMP signaling in F. tularensis.


Subject(s)
Biofilms/drug effects , Cyclic GMP/analogs & derivatives , Francisella/pathogenicity , Gram-Negative Bacterial Infections/microbiology , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biofilms/growth & development , Chitinases/genetics , Chitinases/metabolism , Cyclic GMP/pharmacology , Female , Francisella/drug effects , Francisella/genetics , Francisella/metabolism , Gene Expression Regulation, Bacterial , Humans , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Sequence Analysis, DNA , Virulence/drug effects
15.
Antimicrob Agents Chemother ; 56(6): 2852-7, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22450977

ABSTRACT

FPH-1 is a new class A carbapenemase from Francisella philomiragia. It produces high-level resistance to penicillins and the narrow-spectrum cephalosporin cephalothin and hydrolyzes these ß-lactam antibiotics with catalytic efficiencies of 10(6) to 10(7) M(-1) s(-1). When expressed in Escherichia coli, the enzyme confers resistance to clavulanic acid, tazobactam, and sulbactam and has K(i) values of 7.5, 4, and 220 µM, respectively, against these inhibitors. FPH-1 increases the MIC of the monobactam aztreonam 256-fold and the MIC of the broad-spectrum cephalosporin ceftazidime 128-fold, while the MIC of cefoxitin remains unchanged. MICs of the carbapenem antibiotics imipenem, meropenem, doripenem, and ertapenem are elevated 8-, 8-, 16-, and 64-fold, respectively, against an E. coli JM83 strain producing the FPH-1 carbapenemase. The catalytic efficiencies of the enzyme against carbapenems are in the range of 10(4) to 10(5) M(-1) s(-1). FPH-1 is 77% identical to the FTU-1 ß-lactamase from Francisella tularensis and has low amino acid sequence identity with other class A ß-lactamases. Together with FTU-1, FPH-1 constitutes a new branch of the prolific and ever-expanding class A ß-lactamase tree.


Subject(s)
Bacterial Proteins/metabolism , Francisella/drug effects , Francisella/enzymology , beta-Lactamases/metabolism , Carbapenems/pharmacology , Clavulanic Acid/pharmacology , Doripenem , Ertapenem , Escherichia coli/drug effects , Escherichia coli/enzymology , Imipenem/pharmacology , Meropenem , Microbial Sensitivity Tests , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/pharmacology , Sulbactam/pharmacology , Tazobactam , Thienamycins/pharmacology , beta-Lactams/pharmacology
16.
J Antimicrob Chemother ; 67(10): 2429-33, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22763567

ABSTRACT

OBJECTIVES: Tularaemia is a widespread zoonosis in Europe caused by Francisella tularensis subsp. holarctica. Because of a lack of standardized CLSI-approved antibiotic susceptibility data from European Francisella strains, the antibiotic susceptibilities of a selection of F. tularensis subsp. holarctica isolates originating from Germany, Austria, France, Spain and other European countries were determined. Rarely isolated species and subspecies of Francisella such as Francisella philomiragia, F. tularensis subsp. novicida and F. tularensis subsp. mediasiatica as well as the type strain of Francisella hispaniensis were included in this study. METHODS: MIC data were obtained using cation-adjusted Mueller-Hinton broth with a 2% growth supplement. The broth microdilution testing system comprised 14 antibiotics, including gentamicin, streptomycin, ciprofloxacin and tetracycline. RESULTS: All of the 91 strains tested were susceptible to aminoglycosides, quinolones, tetracycline and chloramphenicol. The antimicrobial susceptibility of rare Francisellae was similar to the antibiotic profile of F. tularensis subsp. holarctica strains. For erythromycin, we detected two geographically distinct groups of F. tularensis subsp. holarctica isolates in western Europe. One group was resistant and the other one was susceptible. Both groups overlapped in a small region in Germany. CONCLUSIONS: Being performed in accordance with CLSI criteria, this study provides reliable data on antibiotic susceptibility patterns of European Francisella isolates. The standardized methodology of this study can be used for testing of suspicious colonies from clinical specimens for therapeutic guidance. Based on the results, aminoglycosides or quinolones are recommended as first-choice antibiotics for the therapy of F. hispaniensis, F. philomiragia or F. tularensis subsp. novicida infections in immunocompromised patients.


Subject(s)
Anti-Bacterial Agents/pharmacology , Francisella/drug effects , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/standards , Tularemia/microbiology , Tularemia/veterinary , Animals , Environmental Microbiology , Europe , Francisella/classification , Francisella/isolation & purification , Humans
17.
Dis Aquat Organ ; 98(1): 57-62, 2012 Feb 17.
Article in English | MEDLINE | ID: mdl-22422129

ABSTRACT

A total of 30 isolates of Francisella noatunensis subsp. noatunensis isolated from Atlantic cod Gadus morhua L. were tested for susceptibility, in the form of minimal inhibitory concentration (MIC) values, against the following antibacterial agents: flumequine, oxolinic acid, ciprofloxacin, florfenicol, oxytetracycline, erythromycin, streptomycin sulphate, trimetoprim/sulphadiazine and rifampin. All the isolates had a low susceptibility to oxytetracycline, trimetoprim/sulphadiazine (Tribrissen®), erythromycin, ciprofloxacin and streptomycin with MIC values of 64, 64 to 128, 16, 8 and 32 to 128 µg ml-1, respectively. The strains were, on the other hand, susceptible to florfenicol, oxolinic acid, flumequine and rifampin with MIC values of 0.5, 0.25, 0.25 and 0.25 to 1 µg ml-1, respectively.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Fish Diseases/microbiology , Francisella/drug effects , Gadus morhua , Gram-Negative Bacterial Infections/veterinary , Animals , Fish Diseases/epidemiology , Francisella/classification , Francisella/isolation & purification , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Microbial Sensitivity Tests , Norway/epidemiology
18.
Antimicrob Agents Chemother ; 54(1): 244-53, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19917753

ABSTRACT

Francisella tularensis requires iron (Fe) for growth, but the biologic sources of Fe for this organism are largely unknown. We found that Francisella sp. growing in broth culture or within human macrophages can acquire Fe from the two major host Fe-binding proteins, lactoferrin (Lf) and transferrin (Tf). Fe acquisition is a potential target for novel therapies. Gallium (Ga) is a transition metal that interferes with cellular Fe metabolism by competing with Fe for uptake/utilization. Growth of either F. tularensis live vaccine strain (LVS) or Francisella novicida was inhibited by >or=2 microM Ga chelated to Tf or Lf, with GaLf being somewhat more potent. Francisella spp. express two Fe-containing antioxidant enzymes, catalase (KatG) and Fe cofactored superoxide dismutase (FeSOD). Growth of LVS with 10 muM GaTf or GaLf led to a dramatic decrease in bacterial catalase activity and in FeSOD activity that was associated with an increased susceptibility to H(2)O(2). Ga also protected mice from intranasal challenge with F. novicida. Whereas 100% of the F. novicida-infected mice died by day 9, 75% of the mice receiving Ga continued to survive to at least day 15. Thus, a single intranasal dose of Ga followed by daily intraperitoneal Ga at a dose tolerated by the animals resulted in prolonged survival. These data support the potential utility of Ga as a therapy for F. tularensis infection of the lung.


Subject(s)
Francisella/drug effects , Francisella/metabolism , Gallium/pharmacology , Gallium/therapeutic use , Gram-Negative Bacterial Infections/metabolism , Iron/metabolism , Lung Diseases/drug therapy , Lung Diseases/metabolism , Adult , Animals , Antioxidants/metabolism , Catalase/metabolism , Drug Resistance, Bacterial , Female , Francisella tularensis , Gram-Negative Bacterial Infections/microbiology , Humans , Hydrogen Peroxide/pharmacology , Lung Diseases/microbiology , Macrophages/microbiology , Mice , Mice, Inbred BALB C , Superoxide Dismutase/metabolism , Tularemia/metabolism , Tularemia/microbiology
19.
Biochem Biophys Res Commun ; 396(2): 246-51, 2010 May 28.
Article in English | MEDLINE | ID: mdl-20399752

ABSTRACT

Francisella infects the lungs causing pneumonic tularemia. Focusing on the lung's host defense, we have examined antimicrobial peptides as part of the innate immune response to Francisella infection. Interest in antimicrobial peptides, such as the cathelicidins, has grown due their potential therapeutic applications and the increasing problem of bacterial resistance to commonly used antibiotics. Only one human cathelicidin, LL-37, has been characterized. Helical cathelicidins have also been discovered in snakes including the Chinese King Cobra, Naja atra (NA-CATH). Four synthetic 11-residue peptides (ATRA-1, -2, -1A and -1P) containing variations of a repeated motif within NA-CATH were designed. We hypothesized that these smaller synthetic peptides could have excellent antimicrobial effectiveness with shorter length (and less cost), making them strong potential candidates for development into broad-spectrum antimicrobial compounds. We tested the susceptibility of F. novicida to four ATRA peptides, LL-37, and NA-CATH. Two of the ATRA peptides had high antimicrobial activity (microM), while the two proline-containing ATRA peptides had low activity. The ATRA peptides did not show significant hemolytic activity even at high peptide concentration, indicating low cytotoxicity against host cells. NA-CATH killed Francisella bacteria more quickly than LL-37. However, LL-37 was the most effective peptide against F. novicida (EC50=50 nM). LL-37 mRNA was induced in A549 cells by Francisella infection. We recently demonstrated that F. novicida forms in vitro biofilms. LL-37 inhibited F. novicida biofilm formation at sub-antimicrobial concentrations. Understanding the properties of these peptides, and their endogenous expression in the lung could lead to potential future therapeutic interventions for this lung infection.


Subject(s)
Antimicrobial Cationic Peptides/pharmacology , Biofilms/drug effects , Cathelicidins/pharmacology , Francisella/drug effects , Amino Acid Sequence , Antimicrobial Cationic Peptides/chemistry , Antimicrobial Cationic Peptides/genetics , Cathelicidins/chemistry , Cell Line , Francisella/physiology , Humans , Molecular Sequence Data
20.
BMC Microbiol ; 10: 123, 2010 Apr 23.
Article in English | MEDLINE | ID: mdl-20416090

ABSTRACT

BACKGROUND: Macrolide antibiotics are commonly administered for bacterial respiratory illnesses. Azithromycin (Az) is especially noted for extremely high intracellular concentrations achieved within macrophages which is far greater than the serum concentration. Clinical strains of Type B Francisella (F.) tularensis have been reported to be resistant to Az, however our laboratory Francisella strains were found to be sensitive. We hypothesized that different strains/species of Francisella (including Type A) may have different susceptibilities to Az, a widely used and well-tolerated antibiotic. RESULTS: In vitro susceptibility testing of Az confirmed that F. tularensis subsp. holarctica Live Vaccine Strain (LVS) (Type B) was not sensitive while F. philomiragia, F. novicida, and Type A F. tularensis (NIH B38 and Schu S4 strain) were susceptible. In J774A.1 mouse macrophage cells infected with F. philomiragia, F. novicida, and F. tularensis LVS, 5 microg/ml Az applied extracellularly eliminated intracellular Francisella infections. A concentration of 25 microg/ml Az was required for Francisella-infected A549 human lung epithelial cells, suggesting that macrophages are more effective at concentrating Az than epithelial cells. Mutants of RND efflux components (tolC and ftlC) in F. novicida demonstrated less sensitivity to Az by MIC than the parental strain, but the tolC disc-inhibition assay demonstrated increased sensitivity, indicating a complex role for the outer-membrane transporter. Mutants of acrA and acrB mutants were less sensitive to Az than the parental strain, suggesting that AcrAB is not critical for the efflux of Az in F. novicida. In contrast, F. tularensis Schu S4 mutants DeltaacrB and DeltaacrA were more sensitive than the parental strain, indicating that the AcrAB may be important for Az efflux in F. tularensis Schu S4. F. novicida LPS O-antigen mutants (wbtN, wbtE, wbtQ and wbtA) were found to be less sensitive in vitro to Az compared to the wild-type. Az treatment prolonged the survival of Galleria (G.) mellonella infected with Francisella. CONCLUSION: These studies demonstrate that Type A Francisella strains, as well as F. novicida and F. philomiragia, are sensitive to Az in vitro. Francisella LPS and the RND efflux pump may play a role in Az sensitivity. Az also has antimicrobial activity against intracellular Francisella, suggesting that the intracellular concentration of Az is high enough to be effective against multiple strains/species of Francisella, especially in macrophages. Az treatment prolonged survival an in vivo model of Francisella-infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Epithelial Cells/microbiology , Francisella/drug effects , Macrophages/microbiology , Animals , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Cell Line , Humans , Lepidoptera/microbiology , Mice , Microbial Sensitivity Tests , Microbial Viability/drug effects , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL